$ICUI

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

Woolson Daniel (VP, GM-Infusion Capital) sold 5,417 shares of ICU MEDICAL INC/DE (ICUI) at $181.33 ($0.98M total) on 2026-08-13.

ICU Medical (ICUI) reported Q2 strength in Infusion Systems and Consumables, citing North America growth, record pump and consumables quarters, and margin gains from IT integration and facility consolidation. CEO Vivek Jain said growth came from competitive wins and earlier installations, with organic Infusion Systems growth at or above 6%. Tariffs and currency headwinds were partly offset by execution. Shares were $179.30.

Sousa Ben (Chief Information Officer) sold 2,250 shares of ICU MEDICAL INC/DE (ICUI) at $178.32 ($0.40M total) on 2026-08-12.

Voigtlander Christian B. (Chief Operating Officer) sold 8,929 shares of ICU MEDICAL INC/DE (ICUI) at $182.93 ($1.63M total) on 2026-08-11.

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.

ICU MEDICAL INC/DE (ICUI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., August 6, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, tod

ICU Medical (NASDAQ: ICUI) is set to report Q2 earnings Thursday after market close. The prior quarter revenue was $525.8 million, down 12.3% year over year, and it beat EPS estimates. For Q2, analysts expect revenue to decline about 2% year over year. The article cites an average analyst price target of $176.63 versus a $172 share price.